bortezomib 
takeda
['mmsm']
presenting our initial results of dara-rvd in high risk smm. 80% high risk per 20/2/20. 90% orr with 50% mrd negativity rate. plan for response adaptive therapy based on mrd status #mmsm #asco22 
Medical Oncologist | Myeloma Physician/Clinical Investigator | @danafarber @harvardmed #multiplemyeloma #mmsm